學術研究成果/Publication
基本資料/Profiles
姓名/Name: 賴宥良 性別/Gender:
英文姓名/
English Name:
Yo-Liang Lai 英文縮寫/
Abbreviation:
任職單位/
Affiliation:
1.醫學院醫學系學士班放射腫瘤學科(兼任助理教授) / Department of Radiation Oncology (Part-Time Assistant Professor)
2.中國附醫放射腫瘤部粒子放射治療科(主治醫師) / (Attending Physician)
3.北港醫院放射腫瘤科(兼任醫師) / ()
Email: 022687@tool.caaumed.org.tw
研究專長/Fields of Specialty
1﹒ Radiation Oncology
 
期刊論文/Journal Paper
(作者群,論文題目,期刊名稱,出版年月,卷號(期別):頁次起迄)
SCI論文 劉佳鑫、賴宥良(Yo-Liang Lai)、沈培鈞、劉修誠(LIU, HSIU-CHENG)、蔡孟欣(TSAI MENG-HSIN)、王又德(Yu-De Wang)、林文仁(LIN WEN-JEN)、(Fang-Hsin Chen)、(Chia-Yang Li)、(Shu-Chi Wang)、洪明奇(Mien-Chie Hung)、鄭維中(Cheng, Wei-Chung)*,DriverDBv4: a multi-omics integration database for cancer driver gene research,NUCLEIC ACIDS RESEARCH,2023 Nov,2023():1-7
SCI論文 劉佳鑫、劉淑萱(Shu-Hsuan)、賴宥良(Yo-Liang Lai)、(Yi-Chun Cho)、(Fang-Hsin Chen)、林莉婕(Lin, Li-Jie)、(Pei-Hua Peng)、(Chia-Yang Li)、(Shu-Chi Wang)、(Ji-Lin Chen)、吳恒祥(Wu, Heng-Hsiung)、(Min-Zu Wu)、佘玉萍(Yuh-Pyng Sher)、鄭維中(Cheng, Wei-Chung)*、許凱文(Hsu, Kai-Wen)*,Using bioinformatics approaches to identify survival-related oncomiRs as potential targets of miRNA-based treatments for lung adenocarcinoma,Computational and Structural Biotechnology Journal,2022 Aug,():
SCI論文 賴宥良(Yo-Liang Lai)、劉佳鑫、(Shu-Chi Wang)、(Shu-Pin Huang)、(Yi-Chun Cho)、鮑柏穎(Bao, Bo-Ying)、(Chia-Cheng Su)、(Hsin-Chih Yeh)、(Cheng-Hsueh Lee)、(Pai-Chi Teng)、(Chih-Pin Chuu)、(Deng-Neng Chen)、(Chia-Yang Li)*、鄭維中(Cheng, Wei-Chung)*,Identification of a Steroid Hormone-Associated Gene Signature Predicting the Prognosis of Prostate Cancer through an Integrative Bioinformatics Analysis,Cancers,2022 Mar,14(6):1565
SCI論文 (Pai-Chi Teng)、(Shu-Pin Huang)、劉佳鑫、(Ting-Yi Lin)、卓奕君、賴宥良(Yo-Liang Lai)、(Shu-Chi Wang)、(sin-Chih Yeh)、(Chih-Pin Chuu)、(Deng-Neng Chen)、鄭維中(Cheng, Wei-Chung)*、(Chia-Yang Li)*,Identification of DNA Damage Repair-Associated Prognostic Biomarkers for Prostate Cancer Using Transcriptomic Data Analysis,INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES,2021 Oct,22(221):11771
SCI論文 劉淑萱(Liu, Shu-Hsuan)、許凱文(Hsu, Kai-Wen)、賴宥良(Yo-Liang Lai)、(Lin YF)、(Chen FH)、(Peng PH)、林莉婕(Lin, Li-Jie)、吳恒祥(Wu, Heng-Hsiung)、(Chia-Yang Li)、Wang SC、(Wu MZ)、佘玉萍(Yuh-Pyng Sher)*、鄭維中(Cheng, Wei-Chung)*,Systematic identification of clinically relevant miRNAs for potential miRNA-based therapy in lung adenocarcinoma,Molecular Therapy-Nucleic Acids,2021 Sep,25():1-10
SCI論文 (Jeffrey Yung-chuanChao)、(Hsin-Chuan Chang)、(Jeng-Kai Jiang)、(Chih-Yung Yang)、(Fang-Hsin Chen)、賴宥良(Yo-Liang Lai)、林文仁(Lin, Wun-Ren)、(Chia-Yang Li)、(Shu-Chi Wang)、(Muh-Hwa Yang)、(Yu-Feng Lin)*、鄭維中(Cheng, Wei-Chung)*,Using bioinformatics approaches to investigate driver genes and identify BCL7A as a prognostic gene in colorectal cancer,Computational and Structural Biotechnology Journal,2021 Jul,19():3922-3929
SCI論文 (Yumei Qi)、賴宥良(Yo-Liang Lai)、沈培鈞、(Fang-Hsin Chen)、林莉婕(Lin, Li-Jie)、吳恒祥(Wu, Heng-Hsiung)、(Pei-Hua Peng)、許凱文(Hsu, Kai-Wen)*、鄭維中(Cheng, Wei-Chung)*,Identification and validation of a miRNA-based prognostic signature for cervical cancer through an integrated bioinformatics approach,Scientific Reports,2020 Dec,10(1):22270
SCI論文 劉淑萱(Liu, Shu-Hsuan)、沈培鈞、(Chen-Yang Chen)、許安霓、卓奕君、賴宥良(Yo-Liang Lai)、(Fang-Hsin Chen)、(Chia-Yang Li)、(Shu-Chi Wang)、(Ming Chen)、(I-Fang Chung)、鄭維中(Cheng, Wei-Chung)*,DriverDBv3: a multi-omics database for cancer driver gene research,NUCLEIC ACIDS RESEARCH,2019 Nov,():
SCI論文 吳偉榤(WU WEI-CHIEH)、張宜儒(Chang, Yi-Ru)、賴宥良(Yo-Liang Lai)、蕭安成(An-Cheng Shiau)*、梁基安(Ji-An Liang)、簡君儒(Chun-Ru Chien)、郭于誠(Yu-Cheng Kuo)、陳尚文(Shang-Wen Chen)*,Impact of body-mass factors on setup displacement during pelvic irradiation in patients with lower abdominal cancer,Radiology and Oncology,2019 Apr,0017():
SCI論文 賴宥良(Yo-Liang Lai)、蘇圓智(Yuan-Chih Su)、高嘉鴻(Chia-Hung Kao)、梁基安(Ji-An Liang)*,Increased risk of varicella-zoster virus infection in patients with breast cancer after adjuvant radiotherapy: A population-based cohort study,PLoS One,2019 Jan,0():
Other論文 吳偉榤(Wei-Chieh Wu)、賴宥良(Yo-Liang Lai)、梁基安(Liang, Ji-An)*,Salvage Radiotherapy for Biochemical Recurrence after Radical Prostatectomy: Experience of a Single Institution,放射治療與腫瘤學,2018 Jan,2(3):1-9
SCI論文 賴宥良(Yo-Liang Lai)、郭于誠(Yu-Cheng, Kuo)、賴學洲(Hsueh-Chou Lai)、彭成元(Cheng-Yuan Peng)、王耀慶(Yao-Ching Wang)、梁基安(Liang, Ji-An)、陳尚文(Shang-Wen Chen)*,Early radiation-induced liver toxicities are associated with poor survival in patients with advanced hepatocellular carcinoma,Asia-Pacific Journal of Clinical Oncology,2016 Dec,12(4):437-443
SCI論文 賴宥良(Yo-Liang Lai)、吳駿一(Wu, Chun-Yi)、趙坤山(Kun-San Chao)*,Biological imaging in clinical oncology: radiation therapy based on functional imaging,International Journal of Clinical Oncology,2016 Aug,21(4):626-632
Other論文 賴宥良(Yo-Liang Lai)、游浚彥(Chun-Yen Yu)、梁基安(Ji-An Liang)、陳尚文(Shang-Wen Chen)*,Impact of the body-mass factors on set-up displacement in patients treated with pelvic irradiation for gynecological cancer with daily on-line image guidance,放射治療與腫瘤學,2014 Mar,21(1):21-30
SCI論文 賴宥良(Yo-Liang Lai)、楊世能(Shih-Neng Yang)、梁基安(Ji-An Liang)、王耀慶(Yao-Ching Wang)、游浚彥(Chun-Yen Yu)、蘇經雄(Ching-Shiung Su)、陳尚文(Shang-Wen Chen)*,Impact of body-mass factors on setup displacement in patients with head and neck cancer treated with radiotherapy using daily on-line image guidance,Radiation Oncology,2014 Jan,9(19):1-8
 
研討會論文/Conference Papers
(發表主題或論文名稱,研討會名稱,演講地點,研討會期間,受邀演講題目)
1﹒ ,Role & Evidence of Treatment Modalities in Retroperitoneal, Pelvic sarcoma,臺中福華大飯店 5F CR504會議室 (407台中市安和路129號),2019.12.21 ~ 2019.12.21,Role of radiation therapy in retroperitoneal and pelvic sarcoma
2﹒ Increased risk of varicella-zoster virus infection in breast cancer patients treated with adjuvant radiotherapy: a population–based cohort study,ASTRO 2018 annual meeting,Henry B. Gonzalez Convention Center, san antonio, TX, USA,2018.10.21 ~ 2018.10.24,
3﹒ Effect of body-mass factor on setup displacement during pelvic irradiation in patients with low abdominal cancer,The 6th Taiwan-Japan Radiation Oncology Symposium ( 2018 年第六屆台灣-日本放射線腫瘤研討 ),Taichung, Taiwan,2018.5.19 ~ 2018.5.19,
4﹒ ,2017台灣放射腫瘤學會年度學術研討會Bring Insight into impacts暨海峽兩岸腫瘤高峰論壇,台北醫學大學,2017.12.16 ~ 2017.12.17,PD-L1 as the prognostic immune biomarker for predicting the relapse of locally advanced cervical adenocarcinoma and adenosquamous carcinoma treated with definitive chemoradiation therapy (GYN cancer)
5﹒ PD-L1 as the Prognostic Immune Biomarker for Predicting the Relapse of Locally Advanced Cervical Adenocarcinoma and Adenosquamous Carcinoma Treated with Definitive Chemoradiation Therapy,ASTRO's 59th Annual Meeting, 2017,San Diego Conventional Center, San Diego, CA, US,2017.9.24 ~ 2017.9.27,
6﹒ Salvage Radiotherapy for Biochemical Recurrence after Radical Prostatectomy: Experience of a Single Institution,The 22th Taiwan Joint Cancer Conference,Taipei, Taiwan,2017.5.6 ~ 2017.5.7,
7﹒ Radiation reduces B cell representation in TC-1 mouse lung adenocarcinoma cells,Young Investigator Workshop 2017 Immunosystems-Implications for Cancer Therapy,The University of Texa MD Anderson Cancer Center. Houston, TX, US.,2017.2.9 ~ 2017.2.10,
8﹒ Is involved field target delineation safe in spinal palliative radiotherapy?.,The 18th ECCO – 40th ESMO European Cancer Congress,Messe Wien Exhibition & Congress Center, Vienna, Austria,2015.9.25 ~ 2015.9.29,
9﹒ The interval less then one month between TACE and subsequent hepatic RT dose not contribute to an increased risk of radiation-induced liver disease.,第二十屆台灣癌症聯合學術年會,台北榮民總醫院,2015.5.2 ~ 2015.5.3,
10﹒ MELD Score Is a Predictor of Early Deterioration of Liver Function and Overall Survival in Patients with Hepatocellular Carcinoma Receiving Radiation Therapy,ASTRO’s 56th Annual Meeting,Moscone Center, San Francisco,2014.9.14 ~ 2014.9.17,
11﹒ Impact of the body-related factors on set-up displacement in patients treated with pelvic irradiation for gynecological cancer with daily on-line image guidance,第十八屆台灣癌症聯合學術年會,台大醫院國際會議中心,2013.7.13 ~ 2013.7.14,
 
研究計畫/Research Grant
(研究類型,研究計畫代號,主持人,補助或委託單位名稱,計畫名稱,研究經費,計畫期間)
1﹒ 個別型,NSTC 112-2314-B-039-062,賴宥良(Yo-Liang Lai),陳芳馨、鄭維中(Cheng, Wei-Chung),國科會,以整合性分析鑑定調控頭頸癌輻射抗性之微小核醣核酸,$920000,2023.8.1 ~ 2024.7.31
2﹒ 個別型,DMR-113-050,賴宥良(Yo-Liang Lai),附醫院內計畫,Exosomal miRNAs derived from radiation exposure facilitate liver generation,$200000,2023.8.1 ~ 2024.7.31
3﹒ 個別型,DMR-112-056,賴宥良(Yo-Liang Lai),鄭維中(Cheng, Wei-Chung),附醫院內計畫,To investigate the mechanisms of miRNA mediating radioresistance and immunesuppression on head and neck cancer cell (II),$200000,2022.8.1 ~ 2023.7.31
4﹒ 個別型,DMR-111-075,賴宥良(Yo-Liang Lai),鄭維中(Cheng, Wei-Chung)、陳芳馨,附醫院內計畫,探討微小核糖核酸調控頭頸癌細胞之輻射抗性及免疫抑制機制,$400000,2021.8.1 ~ 2022.7.31
5﹒ 個別型,DMR-110-072,賴宥良(Yo-Liang Lai),鄭維中(Cheng, Wei-Chung),附醫院內計畫,研究微小核醣核酸驅動脂質修飾基因網路影響頭頸癌輻射敏感度之機制(II),$400000,2020.8.1 ~ 2021.7.31
6﹒ 個別型,MOST 108-2314-B-039-060-,賴宥良(Yo-Liang Lai),鄭維中(Cheng, Wei-Chung)、陳芳馨,國科會,微小核醣核酸-基因-脂質修飾網路於頭頸癌抗輻性之機制,$700000,2019.8.1 ~ 2020.7.31
7﹒ 個別型,DMR-109-055,賴宥良(Yo-Liang Lai),鄭維中(Cheng, Wei-Chung),附醫院內計畫,研究微小核醣核酸驅動脂質修飾基因網路影響頭頸癌輻射敏感度之機制,$200000,2019.8.1 ~ 2020.7.31
8﹒ 臨床試驗與研究計畫,CMUH106-REC2-056,趙坤山(Chao, Kun-San),林膺俊、莊伯恒(Po-Heng Chuang)、蔡明宏(TSAI MING HUNG)、賴宥良(Yo-Liang Lai),附醫廠商計畫,一項第一/二期劑量遞增試驗,在併發門靜脈癌栓的肝細胞癌中研究含Lipotecan®同步化學放射療法,$5229349,2017.1.1 ~ 2017.12.31